From a University Spin-Out to a Global Commercial Organization
Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and livestock animal health. The global animal vaccine market is a valuable opportunity growing at an annual rate of 6% and is expected to reach US$12.8 billion by 2025. Livestock illness can lead to human infections, poor feed conversion, or loss of animals, making it a significant economic burden to producers and a threat to human health.
Founded in 2009, Pacific GeneTech was formed to globally commercialize a next-generation animal vaccine platform that was developed at a consortium of leading US universities, and partially funded by the US government. Our proprietary Aegis vaccine platform is the basis for developing new first-in-class or best-in-class recombinant vaccines that provide broad protection against multiple strains and species of pathogens. Since acquiring the rights to the platform that was initially aimed at certain specific diseases in poultry, we have expanded Aegis vaccines into multiple, high-burden diseases across livestock species. In addition to poultry, swine and ruminants, we are developing new solutions for fish and companion animals.
In addition to the original discovery institutions, we have developed research collaborations with other world-leading institutions around the world for the development of our Aegis vaccines and Hercules adjuvant, and to develop new vaccine technologies based on other leading-edge vaccine technologies. We also partner with global and regional animal health companies for the commercialization of our vaccines and adjuvants.
Pacific GeneTech also has a subsidiary, PGTx, that is dedicated to the development of the Pacific GeneTech technologies for human applications.